Coronavirus disease 2019 (COVID-19) often does not require hospitalization. Various neuropsychiatric findings have been associated with COVID-19 cases that require hospitalization. However, data on psychiatric disorders following outpatient treatment for COVID-19, in cases not requiring hospitalization, are limited. Psychotic disorders are characterized by disturbances in emotion, thought, perception, and speech . T here are many causes associated with neuropsychiatric or psychiatric conditions

The aim of this study was to investigate the relationship among sleep quality, impulsivity, anxiety, and depression in individuals with emotional eating behavior. The study was designed as a cross-sectional study. The study included 92 individuals (age 31.29 ± 9.17; female, 67.4% [n = 62]; male, 32.6% [n = 30]) with symptoms of emotional eating but no previous psychiatric diagnosis or treatment. Participants were administered a Structured Clinical Interview for DSM-5 Disorders interview form, a sociodemographic data form, the Emotional Eating Scale, the Beck Depression Scale, the Barratt Impulsivity Scale, the Beck Anxiety Scale, and the Pittsburgh Sleep Quality Index Scale. Emotional eating is positively correlated with anxiety (r = 0.377, p = 0.001), depression (r = 0.375, p = 0.001), impulsivity (r = 0.250, p = 0.016), and poor sleep quality (r = 0.478, p = 0.001). Obese individuals (defined as having a body mass index of 30 or higher) showed higher emotional eating (z = −2.552, p = 0.016) and poorer sleep quality (z = −2.089, p = 0.044) than nonobese individuals, and women showed higher emotional eating (t = 2116, p = 0.037) and poorer sleep quality (z = −2537, p = 0.010) than men. Poor sleep quality was associated with emotional eating. In this relationship, poor sleep quality influenced emotional eating through all mediators, including anxiety and depression (B = 3.491; standardized effect, 0.485; p = 0.001). Poor sleep quality directly influenced emotional eating (B = 2.806; standardized effect, 0.390; p = 0.001). The findings of the study suggest that emotional eating is associated with higher levels of anxiety, depression, impulsivity, and sleep problems, especially in women. It suggests that the interrelationships of psychological factors associated with emotional eating should be investigated.

Semaphorin 5A (SEMA 5A) is a neuroprotein that regulates the formation of excitatory synapses between neurons, important in autoimmunity, inflammatory processes and behaviors. This study aimed to i...

Substance use disorder (SUD) is associated with systemic inflammation and cognitive vulnerability. Peripheral biomarkers may help characterize biological risk across substances and comorbidities. Turkey has experienced a recent rise in methamphetamine and pregabalin misuse, underscoring the need for biomarker-based clinical profiling. A total of 321 inpatients were evaluated in a single inpatient addiction treatment unit in Turkey (2019-2025). Exclusion criteria included severe somatic disease, preexisting psychiatric diagnoses, and incomplete records. Admission data included demographics, primary substance, DSM-5 comorbidities, biomarkers (C-reactive protein [CRP], neutrophil-to-lymphocyte ratio, monocyte-to-lymphocyte ratio, platelet-to-lymphocyte ratio, Systemic Immune-Inflammation Index, Hemoglobin × Albumin/Leukocyte × Platelet Index, Inflammatory Burden Index [IBI]). Analyses used appropriate parametric/non-parametric tests, analysis of covariance, and logistic regression adjusted for age, sex, and comorbidities. IBI and CRP differed significantly across substance groups, with higher inflammatory burden among methamphetamine, alcohol, and MDMA users. After multiple-comparison correction, IBI remained statistically significant, whereas CRP required cautious interpretation. Longer duration of use correlated with higher inflammatory burden. Depressive (14.6%) and anxiety disorders (16.2%) were the most common comorbidities. Bipolar disorder, although infrequent, clustered with higher inflammatory markers. Gender patterns reflected international trends, with greater alcohol/cannabis use in male and earlier, faster dependence progression in female. Multivariate models showed that methamphetamine and alcohol independently predicted elevated IBI after adjustment. IBI and CRP appear to be the most sensitive indicators of systemic inflammation in SUD, particularly in stimulant and alcohol users. Elevation of IBI supports its potential role as a cognition-related biomarker. Findings highlight biological heterogeneity across substances, genders, and comorbidities, and emphasize the need for future prospective studies with neurocognitive testing and structured tobacco documentation.

Aim: The objective of this research was to examine the association between serum uric acid (SUA) and serum uric acid/creatinine ratio (SUA/Cre), disease severity and metabolic syndrome in schizophrenia with a multifaceted etiopathogenesis. Methods: The study comprised 240 participants in total, 120 of whom were healthy controls and 120 of whom were schizophrenia patients. Sociodemographic, clinical and laboratory data was collected and metabolic syndrome was assessed according to the established criteria. SUA and creatinine levels were measured and the SUA/Cre ratio was calculated. The severity of the disease was evaluated utilizing the Positive and Negative Syndrome Scale (PANSS). Statistical analyses were conducted to ascertain correlations and associations. Results: SUA levels and SUA/Cre ratio higher in schizophrenia patients than controls (p=0.14, p=0.010, respectively). SUA/Cre ratio was positively correlated with PANSS negative score (r=0.266, p=0.03). SUA levels were elevated in individuals diagnosed with schizophrenia who also had metabolic syndrome, in comparison to those who did not have metabolic syndrome (p=0.009). Linear regression analyses showed that the association between SUA levels and SUA/Cre ratio and schizophrenia persisted when the effects of gender, age, metabolic syndrome, BMI and smoking were fixed. Conclusions: This study highlights the association of SUA and SUA/Cre ratio with disease severity and metabolic syndrome among individuals diagnosed with schizophrenia.